Document › Details
InSphero AG. (3/16/16). "Press Release: InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury". Schlieren.
|Region||New Orleans, LA|
|Country||United States (USA)|
|Organisation 2||Society of Toxicology (SOT)|
|Product||3D InSight™ Multi-donor Human Liver Microtissues|
3D human liver microtissues comprised of pooled hepatocytes from multiple donors offers more genetically diverse model for DILI detection and prediction.
InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, today announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The newest liver model is being introduced at the Society of Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana. Failure of drugs during late phases of the drug discovery process costs the pharmaceutical industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to accurately distinguish between known hepatotoxicants and structurally-related non-toxic analogs. The new multi-donor microtissues offer the same structural and functional robustness of single-donor microtissues, but provide a more diverse genetic background to help mitigate bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome P450 enzymes.
Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes from 5 male and 5 female donors, multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of cells for microtissue production. This makes them an ideal tool for in vitro DILI detection and prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”
Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with Kupffer cells, enabling detection of immune-mediated toxicity.
To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more about InSphero visit www.insphero.com.
For more information about InSphero, visit www.insphero.com.
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.
Follow us on Twitter and www.insphero.com.
Record changed: 2016-03-31
More documents for InSphero (Group)
-  InSphero AG. (2/1/16). "Press Release: InSphero Inc. Streamlines 3D Microtissue Business Operations in US". Schlieren....
-  InSphero AG. (1/21/16). "Press Release: InSphero Adds Head of Sales, Expands Global Sales Team". Schlieren....
-  InSphero AG. (10/15/15). "Press Release: InSphero Adds Chief Financial Officer to Senior Management Team". Schlieren....
-  InSphero AG. (7/8/15). "Press Release: InSphero AG Secures CHF 20 Million Series C Financing". Schlieren....
-  Biognosys AG. (3/6/15). "Press Release: HRM – a New Standard for Comprehensive Proteome Profiling. Biognosys’ New DIA Workflow a Powerful Approach for High Content Protein Quantification". Zürich-Schlieren....
-  Protea Biosciences Group, Inc.. (10/2/14). "Press Release: Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues". Morgantown, WV & Schlieren....
-  Protea Biosciences Group, Inc.. (7/9/14). "Press Release: Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies". Morgantown, WV & Schlieren....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]